Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.68 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7062961 | 0.94 | TACR1 (0.76) | TACR1MMP9MMP8MMP2ECE1 | |
| SCHEMBL7067777 | 0.91 | TACR1 (0.67) | TACR1MMP9MMP8MMP2ECE1 | |
| SCHEMBL7062825 | 0.86 | TACR1 (0.74) | TACR1MMP9MMP8MMP2ECE1 | |
| SCHEMBL7066023 | 0.83 | MMP9 (0.61) | TACR1MMP9MMP8MMP2ECE1 | |
| SCHEMBL7848664 | 0.81 | MC5R (0.61) | TACR1ECE1MAPTSMN1; SMN2HTT | |
| SCHEMBL7846815 | 0.80 | TACR1 (0.68) | TACR1 | |
| SCHEMBL7067703 | 0.80 | TACR1 (0.68) | TACR1 | |
| SCHEMBL7846982 | 0.79 | BRS3 (0.60) | TACR1MAPTSMN1; SMN2 | |
| SCHEMBL7064414 | 0.78 | MMP9 (0.59) | TACR1MMP9MMP8MMP2ECE1 | |
| SCHEMBL7856881 | 0.77 | TACR1 (0.57) | TACR1MMP9MMP8GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065007-A1 | NK1 receptor antagonists | CRESWELL MARK WALLACE (US) | 2003-04-03 | — | — | US | claimed |
| US-6472418-B1 | Non-peptide NK1 receptors antagonists | WARNER-LAMBERT COMPANY | 2002-10-29 | — | — | US | claimed |
| EP-1140914-A1 | NON-PEPTIDE NK1 RECEPTORS ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000037462-A1 | NON-PEPTIDE NK1 RECEPTORS ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| US-20030065007-A1 | NK1 receptor antagonists | CRESWELL MARK WALLACE (US) | 2003-04-03 | — | — | US | disclosed |
| US-6472418-B1 | Non-peptide NK1 receptors antagonists | WARNER-LAMBERT COMPANY | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065007-A1 | NK1 receptor antagonists | HRH1, HRH4, HRH2 | TACR1 18/4885MMP9 4069/4885MMP8 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.